Managers / Q2 2025 · view latest →
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589 · 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591 · 9148477000
Summary
Regeneron Pharmaceuticals, Inc. reported $1.5B in U.S.-listed holdings across 4 positions for Q2 2025.
The portfolio is heavily concentrated: ALNY alone accounts for 97.6% of reported value.
Compared with Q1 2025, the fund opened 0 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $1.5B
Quarter-over-Quarter Changes full breakdown →
vs Q1 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| 2seventy Bio, Inc. | SOLD OUT | −1.25M | 0 | −$6M | $0 |
| Bluebird Bio, Inc. | SOLD OUT | −21.0K | 0 | −$102,480 | $0 |
| ALNYAlnylam Pharmaceuticals, Inc. | HELD | +0 | 4.44M | +$249M | $1.4B |
| NTLAIntellia Therapeutics, Inc. | HELD | +0 | 3.70M | +$8M | $35M |
| Adverum Biotechnologies, Inc. | HELD | +0 | 180.9K | −$401,618 | $388,954 |
| Adicet Bio, Inc. | HELD | +0 | 968.2K | −$140,386 | $590,592 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ALNYAlnylam Pharmaceuticals, Inc.history → | Common Stock | 97.60% | $1.4B | 4.44M |
| 2 | NTLAIntellia Therapeutics, Inc.history → | Common Stock | 2.34% | $35M | 3.70M |
| 3 | Adicet Bio, Inc. | Common Stock | 0.04% | $590,592 | 968.2K |
| 4 | Adverum Biotechnologies, Inc. | Common Stock | 0.03% | $388,954 | 180.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $48M | 2 | May 8, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $34M | 2 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $700M | 4 | Nov 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $1.5B | 4 | Aug 1, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $1.2B | 6 | May 2, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $1.1B | 6 | Feb 7, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.